Clinical Trials Sponsored by TYRX, Inc.

Total 35443 results

Santen Inc.
MacuSight, Inc.

Completed

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

Diabetic Macular Edema

United States
Esanex Inc.
Serenex, Inc.

Completed

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Hematologic Neoplasms

United States
Essentialis, Inc.
Medpace, Inc.

Completed

Diazoxide Choline in Hypertriglyceridemia

Hypertriglyceridemia

United States
Santen Inc.
MacuSight, Inc.

Completed

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Diabetic Retinopathy | Diabetic Macular Edema

United States
University in Zielona Góra
ConvaTec Inc.

Unknown

Closed Incision Disposable Negative Pressure Wound Therapy in Immediate Postmastectomy Breast Reconstruction

Breast Cancer | Breast Reconstruction

Poland
Astellas Pharma Inc
Seagen Inc.; Agensys, Inc.

Completed

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Neoplasms | Tumors | Medical Oncology

United States, Canada
Vitality in Aging Research Group, Inc.

Withdrawn

VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements

Aging
In-Home Addiction Treatment Institute, Inc.

Suspended

Effects of In-Home Addiction Treatment for First Responders

Substance Use Disorders

United States
EmitBio Inc.

Recruiting

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

COVID-19

United States
VisionCare, Inc.
ORA, Inc.

Recruiting

Multicenter Clinical Study of the SING-IMT in Patients With Late-stage AMD (CONCERTO)

Age-Related Macular Degeneration | Geographic Atrophy

United States
AngioSafe, Inc.
Veranex, Inc.

Recruiting

AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study) (RESTOR-1)

Peripheral Arterial Disease | Peripheral Artery Occlusion

United States
Xoft, Inc.
Icad, Inc.

Terminated

Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (IORT)

Glioblastoma | GBM | Recurrent Glioblastoma | Recurrent GBM

United States
Xoft, Inc.
Icad, Inc.

Active, not recruiting

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

Ductal Carcinoma in Situ | Invasive Ductal Carcinoma

United States, Portugal, Australia
Eisai Inc.
Quintiles, Inc.

Completed

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

Ukraine, Germany, United States, Italy, Czechia
Novan, Inc.
Synteract, Inc.

Completed

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC (B-SIMPLE2)

Molluscum Contagiosum

United States
Genentech, Inc.
Seagen Inc.

Completed

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Mylan Inc.

Completed

Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

Pain | Postoperative Pain | Pain, Acute

United States
Versartis Inc.

Terminated

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Growth Disorders | Pediatric Growth Hormone Deficiency

Japan
Mylan Inc.

Completed

A Survey on Efficacy and Safety in Patients With Endometriosis

Endometriosis

Japan
Mylan Inc.

Completed

Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency

Digestive System Diseases | Pancreatic Diseases | Exocrine Pancreatic Insufficiency

Japan
Mylan Inc.

Completed

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Digestive System Diseases | Pancreatic Diseases | Cystic Fibrosis | Exocrine Pancreatic Insufficiency

Japan
Xoft, Inc.
Icad, Inc.

Completed

Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer

Cervical Cancer

United States
TriHealth Inc.
Orthosensor, Inc.

Unknown

Making Sense Out of Total Knee Sensor Assisted Technology: A Randomized Control Trial

Arthroplasty, Replacement, Knee

United States
MolecuLight Inc.
SerenaGroup, Inc.

Unknown

Evaluation of MolecuLight i:X as an Adjunctive Fluorescence Imaging Tool to Clinical Signs and Symptoms for the Identification of Bacteria-containing Wounds

Wound

United States
Imara, Inc.
Quintiles, Inc.

Completed

A Study of IMR-687 in Healthy Adult Volunteers

Sickle Cell Disease | Sickle Beta 0 Thalassemia | Sickle-Cell; Hb-SC

United States
Eisai Inc.
Quintiles, Inc.

Completed

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Stage IV Melanoma

United Kingdom, United States, Spain, Germany, Italy
Genentech, Inc.
23andMe, Inc.

Completed

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Breast Cancer | Glioblastoma | Colorectal Cancer | Non-Small Cell Lung Cancer | Renal Cell Cancer

United States
Centocor, Inc.
Quintiles, Inc.

Completed

A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector

Rheumatoid Arthritis | Psoriasis | Psoriatic Arthritis | Ankylosing Spondylitis

United States
Seagen Inc.
Genentech, Inc.

Terminated

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States, France, Spain, Belgium, Australia, Germany, Poland, Italy, Czech Republic, Hungary
Ocusoft, Inc.
ORA, Inc.

Completed

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

Keratoconjunctivitis Sicca

United States
Pamlab, Inc.
InfoMedics, Inc.

Completed

Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)

Major Depressive Disorder

United States
Genentech, Inc.
Seagen Inc.

Completed

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
Pamlab, Inc.
InfoMedics, Inc.

Terminated

Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)

Pregnancy

United States
Santen Inc.
MacuSight, Inc.

Completed

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

Dry Eye

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration | Choroidal Neovascularization

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
CrystalGenomics, Inc.
Quintiles, Inc.

Unknown

Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects

Osteoarthritis, Knee | Osteoarthritis, Hip

Germany
Aerovance, Inc.
Quintiles, Inc.

Completed

A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)

Allergic Asthma

United Kingdom
Mylan Technologies Inc.
Mylan Inc.

Active, not recruiting

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Contraception

United States, Canada, Puerto Rico
Santen Inc.
ActualEyes Inc.

Recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States
SerenaGroup, Inc.
DrySee, Inc

Completed

A Comparison Between Two Post-operative Dressings (DrySee)

Surgical Incision

United States
Eisai Inc.
Quintiles, Inc.

Completed

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Non-Small Cell Lung Cancer

Belgium, Korea, Republic of, Italy, United States, Hungary, United Kingdom, Czechia
Athersys, Inc
Medpace, Inc.

Completed

Study to Examine the Effects of MultiStem in Ischemic Stroke

Ischemic Stroke

United States, United Kingdom
Seagen Inc.
Genentech, Inc.

Completed

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
Sequella, Inc.
Quintiles, Inc.

Completed

Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers

Tuberculosis

United States
Zogenix, Inc.
Synteract, Inc.

Completed

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

Migraine

United States
UNC Lineberger Comprehensive Cancer Center
AstraZeneca; Rgenix, Inc.

Recruiting

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Non-Small Cell Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Diffuse Large B-cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
G1 Therapeutics, Inc.

Recruiting

Study of Trilaciclib and Lurbinectidin

Lung Cancer | Small-cell Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Cerulean Pharma Inc.

Terminated

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

Rectal Cancer

United States

3

Subscribe